Urinary Antispasmodic

Culpeper gave angelica for “the stranguary and stoppage of the urine”, and the leaf is the one part of the plant with human trials.

A 2013 parallel, randomised, double-blind, placebo-controlled trial (n=69 men aged 45 and over with two or more nocturnal voids, 8 weeks) of SagaPro, a standardised leaf extract, found the product safe but missed its primary endpoint: nocturnal voids fell in both arms with no significant difference versus placebo. A pre-specified subgroup with reduced nocturnal bladder capacity did improve significantly, which the authors flagged as hypothesis-generating ^{1Reference 1Sigurdsson S et al. · 2013RCTA parallel, randomized, double-blind, placebo-controlled study to investigate the effect of SagaPro on nocturia in men — randomised placebo-controlled trial (RCT)View study →}.

A 2025 pilot RCT (n=143 adults, triple-blind, 6 weeks) of the leaf extract in overactive bladder reported significant improvements in daytime voids, the IPSS storage subscore and quality of life, with a near-significant nocturia effect ^{2Reference 2López-Seoane J et al. · 2025RCTEffects of Angelica archangelica extract on overactive bladder: a pilot randomized controlled trial — randomised placebo-controlled trialView study →}. The two trials point the same way on symptom burden and disagree on the headline endpoint, and both are small.

No smooth-muscle or detrusor assay explains the result. The trials used leaf, while root is the article of commerce and the subject of every traditional listing, so a root tincture is not the tested intervention.

Varuna stem bark is one of the most reliably cited urinary-tract plants in the Ayurvedic and Siddha materia medica, prescribed for painful or difficult urination, retention and urinary infection, and more recently for the lower-urinary-tract symptoms of an enlarged prostate.

Urox, C. nurvala stem bark standardised to 1.5% lupeol with Equisetum arvense and Lindera aggregata, significantly reduced daytime frequency, nocturia and urgency versus placebo in a phase 2 randomised, double-blind, placebo-controlled trial (n=150, 8 weeks) ^{3Reference 3Schoendorfer et al. · 2018RCTUrox (Crataeva nurvala stem bark, Equisetum arvense, Lindera aggregata) for overactive bladder and urinary incontinence — phase 2 randomised, double-blind, placebo-controlled trialView study →}. A paediatric enuresis protocol using the same blend is registered.

Three herbs went into the capsule and the trial measured the capsule. A second positive RCT in urinary stones tested a different C. nurvala combination, so both human datasets for the plant are combinations, and the bladder-tone effect is attributed to lupeol by association rather than by assay.

The standardised leaf press-juice of Bryophyllum pinnatum is the one preparation of this plant with controlled human data, and one of its trials is a randomised, double-blind, placebo-controlled study in postmenopausal women with overactive bladder ^{4Reference 4Betschart C et al. · 2013RCTRandomized, double-blind placebo-controlled trial with Bryophyllum pinnatum versus placebo for the treatment of overactive bladder in postmenopausal womenView study →}.

The flavonoid fraction inhibits porcine detrusor contractility in vitro, and fractionation localises most of the bladder-relaxant activity there, distinct from the bufadienolides ^{5Reference 5Fürer K et al. · 2015In vitroInhibition of porcine detrusor contractility by the flavonoid fraction of Bryophyllum pinnatum — in vitroView study →}. The bufadienolides contribute to detrusor and myometrial relaxation and are also the plant’s cardiac-glycoside principle.

The trial is small, and the evidence belongs to the press-juice preparation. Aqueous leaf juice, ethanol extract, isolated flavonoids and bufadienolide-enriched fractions behave differently.